Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients

Why did OpenAI's valuation hit $500 billion? How will the US government shutdown impact markets? What caused Nike's recent stock surge? Why is Walmart removing artificial food dyes? How is Trump's shutdown affecting federal workers? What is driving gold prices to record highs? Why did Tesla's stock move sharply today?

Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients

benzinga.com/news/health-care/25/09/47941657/mercks-winrevair-cuts-clinical-worsening-risk-by-76-among-hypertension-patients

Merck & Co. Inc. (NYSE:MRK) announced results Tuesday from its Phase 3 HYPERION trial evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class…

This story appeared on benzinga.com, 2025-09-30 13:47:29.